CE

CELLUMED CO., LTD.

Develops bone grafts, artificial joints, and enzymes for the biopharmaceutical sector.

049180 | KO

Overview

Corporate Details

ISIN(s):
KR7049180003
LEI:
Country:
South Korea
Address:
서울특별시 금천구 디지털로 130 402(가산동, 에이스테크노타워 9차), 서울특별시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

CELLUMED CO., LTD. is a biotechnology company specializing in the development and manufacturing of medical devices and biologics. A pioneer in tissue banking, the company provides a range of bone graft materials, including allografts and xenografts, supported by advanced tissue processing technologies. Its product portfolio also includes musculoskeletal medical devices, such as artificial knee joints. Additionally, Cellumed supplies high-quality enzymes essential for the production of RNA-based medicines and vaccines, catering to the biopharmaceutical sector.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-19 00:00
Share Issue/Capital Change
기타주요경영사항 (제3자배정 유상증자 소액공모 철회의 건)
Korean 6.5 KB
2025-09-19 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(유상증자결정)
Korean 31.4 KB
2025-09-19 00:00
Share Issue/Capital Change
[기재정정]소액공모공시서류(지분증권)
Korean 1.9 MB
2025-09-19 00:00
Share Issue/Capital Change
소액공모실적보고서
Korean 26.0 KB
2025-08-26 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 109.8 KB
2025-08-25 00:00
Legal Proceedings Report
투자판단관련주요경영사항 (채권압류 및 전부명령 항고 취하의 건)
Korean 8.2 KB
2025-08-25 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 72.5 KB
2025-08-18 00:00
Legal Proceedings Report
투자판단관련주요경영사항 (집행판결 청구소송 합의의 건)
Korean 13.8 KB
2025-08-14 00:00
Audit Report / Information
반기검토(감사)의견부적정등사실확인(자본잠식률100분의50이상또는자기자본10억원미만포함)
Korean 12.2 KB
2025-08-14 00:00
Interim / Quarterly Report
반기보고서 (2025.06)
Korean 1.9 MB
2025-07-28 00:00
Legal Proceedings Report
소송등의판결ㆍ결정(일정금액이상의청구) (특허권 압류명령)
Korean 12.3 KB
2025-07-25 00:00
Legal Proceedings Report
투자판단관련주요경영사항 (채권압류 및 전부명령 판결에 대한 항고의 건)
Korean 10.0 KB
2025-07-11 00:00
Legal Proceedings Report
투자판단관련주요경영사항 (주식압류명령의 판결에 대한 항고의 건)
Korean 9.3 KB
2025-06-13 00:00
Legal Proceedings Report
소송등의판결ㆍ결정(일정금액이상의청구) (채권압류 및 전부명령)
Korean 12.5 KB
2025-06-13 00:00
Legal Proceedings Report
소송등의판결ㆍ결정(일정금액이상의청구) (주식압류명령)
Korean 14.2 KB

Automate Your Workflow. Get a real-time feed of all CELLUMED CO., LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CELLUMED CO., LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for CELLUMED CO., LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Lipidor AB Logo
Develops topical skin treatments by reformulating drugs with a lipid-based delivery platform.
Sweden
LIPI
Lipocine Inc. Logo
Biopharma developing oral drugs for metabolic & endocrine disorders using delivery technology.
United States of America
LPCN
Liquidia Corp Logo
Develops inhaled therapies for rare cardiopulmonary diseases using proprietary PRINT® technology.
United States of America
LQDA
LISATA THERAPEUTICS, INC. Logo
Oncology firm with a platform for more effective, targeted delivery of anti-cancer drugs.
United States of America
LSTA
Longeveron Inc. Logo
Develops cell therapies for Alzheimer's, aging frailty, and rare infant heart defects.
United States of America
LGVN
Lonza Group AG Logo
A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.
Switzerland
LONN
Lyell Immunopharma, Inc. Logo
Develops durable CAR T-cell therapies for solid tumors & blood cancers by reprogramming T-cells.
United States of America
LYEL
Lyra Therapeutics, Inc. Logo
Developing localized, long-acting therapies for chronic rhinosinusitis (CRS).
United States of America
LYRA
Lytix Biopharma AS Logo
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway
LYTIX
Mabion S.A. Logo
Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.
Poland
MAB

Talk to a Data Expert

Have a question? We'll get back to you promptly.